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The diagnosis of multiple myeloma requires findings of a clonal plasma cell disorder and 
myeloma-related organ dysfunction, such as hypercalcemia, renal insufficiency, anemia, and 
bone disease.
1
 Myeloma evolves from a premalignant state, monoclonal gammopathy of 
undetermined significance,
2
 which is present in 3%–4% of the general population,3 progressing 
to multiple myeloma at a rate of 1% per year.
4
 Prognosis in patients with multiple myeloma 
depends on several variables, including age, performance status, renal function, disease stage, 
β2-microglobulin, and cytogenetic abnormalities.
5
 The treatment of multiple myeloma continues 
to improve due to the development of several new active agents, new drug combinations, and 
autologous transplantation.
6 and 7
 From new information on risk stratification by genetic and 
molecular prognostic markers, chromosomal abnormalities such as deletion of the long arm of 
chromosome 13 [del13(q)] or monosomy 13, and t(4:14)(p16.3;q32) [t(4;14)] have been 
associated with poor prognosis.
8
 Patients with high-risk disease do poorly with most therapies 
and have inferior survival in the absence of complete remission (CR). Their median overall 
survival (OS) is 3 years, even with aggressive therapy.
9
 Thus, questions have arisen now as to 
the best initial and subsequent use of novel drugs, the role of high-dose therapy, and auto- or 
allo-transplantation, endpoints for therapy, and the role of consolidation and maintenance 
therapies. 
THE PROBLEM 
 A 58-year-old white woman was found to be anemic with hemoglobin of 7 g/dL (normal, 
11.5–15.5). She underwent screening colonoscopy and was placed on iron supplementation. 
She then developed blurred vision, saw an optometrist, was found to have a retinal 
hemorrhage, and was referred to an ophthalmologist who obtained laboratory testing, the 
results (normal range bracketed) of which revealed elevation of serum total protein at 15.8 
g/dL (6–8.4) and serum IgG of 11,316 mg/dL (717–1,411), borderline creatinine elevation at 
1.4 mg/dL (0.7–1.4), and decreased IgA 22 mg/dL (78–391), and IgM 13 mg/dL (53–334). 
Serum calcium was normal at 8.9 mg/dL (8.5–10.5). Further evaluation revealed serum IgG 
kappa monoclonal protein, 9.16 g/dL, by serum protein electrophoresis and immunofixation 
electrophoresis. Serum β2-microglobulin was elevated (7 mg/dL; normal, 0.3–1.9), albumin 
was decreased (2.4 g/dL; normal, 3.5–5.0), and the lactate dehydrogenase (LDH) was within 
normal range (164 U/L; normal, 100–220). Complete blood cell count showed white blood 
cells 3.8 x 10
3
/µL (normal, 3.8–11.0), Hemoglobin 5.7 g/dL (normal, 11.5–15.5), hematocrit 
18.8% (normal, 36.0%–46.0%), and platelets 152 x 103/µL (normal, 150–400), with 4% 
circulating plasma cells in peripheral blood (see Figure 1). Bone marrow aspirate smear (see 
Figure 2) and core biopsy (see Figure 3) identified involvement by plasma cell neoplasm 
comprising 70% of the total marrow cellularity. Immunostains performed on the core biopsy 
demonstrated that markedly increased plasma cells were positive for CD138 (syndecan-1) 
and kappa light chains, and negative for CD79a (mb-1; Ig-α), CD56 (NCAM-1), cyclin D1, 
and lambda light chain. Cytogenetics demonstrated a normal female karyotype. Interphase 
fluorescence in situ hybridization (FISH) analysis of the marrow specimen showed 
monosomy 13 (see Figure 4), and IgH/FGFR3 fusion, t(4;14) (see Figure 5). Skeletal survey 
identified partial compression fracture at T8 vertebral body. 
     
 
 
Figure 1. Peripheral blood smear (x50, Wright stain) shows normocytic anemia with remarkable 
rouleaux formation in red blood cells and circulating plasma cells. 
 
 
 
 
Figure 2. Bone marrow aspirate smear (x50, Wright stain) shows markedly increased atypical 
plasma cells with anisocytosis, and occasional immature forms with prominent nucleoli or double 
nuclei (not shown in the photograph). 
 
 
 Figure 3. Bone marrow core biopsy (x20, hematoxylin and eosin) shows increased cellularity for 
age (approximately 60%) with reduced trilineage hematopoietic maturation, and markedly increased 
plasma cells with atypia and immature forms with nucleoli replacing approximately 70% of the 
marrow cellularity. Immunohistochemical stains (not shown in the picture) show the plasma cells 
are positive for CD138 and kappa light chain, and negative for lambda light chain, CD56, CD79a 
and cyclin D1. 
 
 
 
Figure 4. Interphase FISH picture shows a cell with two blue signals from normal two centromeres, 
one red signal from the locus-specific 13q14 (Rb1) probe, and one green signal from 13q34 
(LAMP1) probe. This pattern demonstrates monosomy 13. 
 
 
 
 
 
 
 
 
 
Figure 5. Interphase FISH picture shows a cell with a green signal from the locus-specific 14q32 
(IgH) probe, an orange signal from 4p16 (FGFR3) probe, and fusion of two signals in proximity. 
This pattern demonstrates t(4;14)(p16;q32). 
 
By Durie-Salmon Stage
10
 and the International Staging System
11
 (ISS) the patient had stage III, 
high-risk myeloma. She received packed red blood cell transfusions. Treatment with bortezomib, 
revlimid, and decadron (VRD), was complicated by moderate to severe fatigue, diarrhea, 
neuropathy, dysgeusia, and weight loss. The serum monoclonal paraprotein decreased to 0.16 g/dL 
with no detectable urine monoclonal protein after therapy. A very good partial remission was 
achieved after five cycles of therapy. 
Several questions arise in the management of this patient with high-risk multiple myeloma. Is 
bortezomib-based therapy necessary to overcome her high-risk disease
12
? Should a change of the 
initial treatment regimen be used if she does not achieve initial CR? Will autologous stem cell 
transplantation (ASCT) or tandem ASCT (a tandem or double transplant is a procedure involving 
the administration of a second cycle of high-dose melphalan and a second stem-cell infusion within 
a few months after the first procedure.) improve her chance of OS and is it currently the standard of 
care? Or should allogeneic marrow transplantation be considered for this patient with high-risk 
disease, despite higher treatment-related mortality? What are proper endpoints of therapy: CR, 
progression-free survival (PFS), and/or OS? Finally, what is the appropriate maintenance therapy 
for this patient? 
EXPERT OPINION 1 
The identification and definition of high-risk myeloma represents an important clinical question for 
newly diagnosed myeloma patients. High-risk disease was previously defined as deletion of 
chromosome 13 or signs of “proliferation” such as an elevated lactate dehydrogenase (LDH),13 
elevated β2-microglobulin, or increased plasma cell labeling index, but has more recently been 
replaced with FISH or gene expression based definitions of high-risk disease.
14
 While the use of ISS 
stage 3 or high LDH does have value, the presence of deletion of 17p, t(4:14), t(14:16),
9 and 15
 as 
well as the presence of circulating plasma cells, is now used more commonly to define high-risk 
patients at the time of diagnosis.
16
 
Practically, it is important to know that if one is to rely on FISH or gene expression profiling at the 
time of diagnosis, the test must be performed on purified plasma cells, as the use of unselected 
FISH may result in false negative allocation of patients to a standard risk category. The presence or 
absence of a FISH-defined risk category may be further enhanced through the use of the ISS stage. 
Specifically, with the t(4:14) translocation, prognosis was defined further by the concomitant ISS 
stage such that the outcomes for patients with t(4:14) who had ISS stage 1 disease was very 
different from those with ISS stage III disease.
17
 Thus, older techniques and newer molecular tests 
are likely complementary, and are useful as one seeks to make optimal decisions when treating 
patients. 
Conventional approaches such as combinations of alkylators and corticosteroids are not effective in 
improving outcomes for patients with high-risk disease. Additionally, many randomized studies 
now have demonstrated that the use of allogenic transplant does not improve outcomes for these 
patients. The Blood and Marrow Transplant Clinical Trials Network group presented results 
recently of a randomized trial comparing tandem autologous transplant with autologous followed by 
non-myeloablative allogenic transplant and demonstrated that among both standard- and high-risk 
patients, there was no improvement in PFS or OS.
18 and 19
 Furthermore, the use of allogenic 
transplant is associated with very high treatment-related mortality as well as complications of graft-
versus-host disease and relapse, making this a much less attractive option even for those with high-
risk disease where the graft-versus-myeloma effect may not have sufficient time to be a long-term 
disease control mechanism. 
For the specific high-risk feature described in the current case, there have been signs of improved 
outcomes through the use of new treatment approaches. A study of bortezomib-thalidomide-
dexamethasone induction, followed by high-dose therapy and autologous transplant followed by 
consolidation and maintenance therapy suggested that among those randomized to receive 
thalidomide-dexamethasone induction, there continued to be a detrimental impact on PFS for 
patients who carried the t(4:14) translocation at diagnosis.
20
 However, for patients randomized to 
receive bortezomib-thalidomide-dexamethasone at induction, the negative impact of t(4:14) was no 
longer seen, suggesting that the combination of a proteasome inhibitor and immunomodulatory drug 
(IMiD) at diagnosis and as consolidation therapy is a strategy that can be used to help overcome or 
mitigate the negative impact of high-risk features at diagnosis. 
While the use of combination therapy in the induction and consolidation phase may serve to help 
mitigate certain high-risk subsets of myeloma, it is clear this is not always the case for all poor-risk 
patients. However, it is important to realize that in an era where we have many more effective 
agents at our disposal, it is no longer appropriate to treat with induction therapy and have no plans 
for consolidation or maintenance therapy. This is especially the case among patients with high-risk 
disease, where patients may achieve a CR but in the absence of ongoing therapy are likely to rapidly 
relapse, often with a more resistant and genetically complex plasma cell clone. For this reason, the 
concept of CR duration, first introduced by Barlogie and colleagues, is of value.
21
 
In summary, the identification of patients with high-risk features at initial diagnosis is an important 
part of treatment planning. While the absence of high-risk features does not change the initial 
recommendation for combination therapy with a proteasome inhibitor, IMiD, and steroids, it does 
have an impact on the approach towards high-dose therapy, consolidation, and maintenance 
therapy. For patients with high-risk disease, the ongoing use of autologous transplant following 
combination induction continues to remain a standard consolidation approach, although this should 
not be where therapy ends. Additonal therapy in the maintenance setting following transplant, also 
with combinations such as VRD, are critically important to ongoing suppression of the malignant 
clone.
22
 Thus, the choice of bortezomib and ImID-based induction, high-dose melphalan-based 
consolidation, and combination maintenance are critical as we attempt to overcome the genomically 
unstable high-risk plasma cell clone. For patients who have disease that has progressed in the 
context of bortezomib-based therapy, the use of newer proteasome inhibitors such as 
carfilzomib,
23 and 24
 or alternative partners with bortezomib such as the histone deactelyase inhibitors 
in combination with bortezomib
25
 may offer some patients a way to overcome bortezomib 
resistance. Trials testing these approaches are currently underway. 
Only through early identification and intense combination-based approaches can we hope to 
improve outcomes for patients with high-risk myeloma. For this particular patient with high-risk 
t(4;14) multiple myeloma, I recommend combination therapy including a proteasome inhibitor and 
IMiD both at induction and as consolidation following high-dose therapy and autologous transplant. 
It is likely that further biological understanding will help in the development of personalized 
approaches for patients with high-risk disease, and perhaps will help us to ultimately cure patients 
with standard- and high-risk myeloma. 
Sagar Lonial, MD 
Department of Hematology and Medical Oncology 
Winship Cancer Institute 
Emory University School of Medicine 
Atlanta, GA 
EXPERT OPINION 2 
Despite tremendous improvements obtained with the introduction of novel drugs such as 
thalidomide, bortezomib, and lenalidomide, patients with high-risk features still have poor 
prognosis. Novel agents, in particular bortezomib, may be able to overcome the adverse influence 
of cytogenetic abnormalities such as t(4;14) in patients with multiple myeloma who are eligible for 
transplantation.
12 and 26
 The Intergroupe Francophone du Myélome (IFM) used a short-term 
bortezomib-dexamethasone regimen and found a significant advantage in both PFS and OS of 
patients with t(4;14), in comparison with patients treated with the combination of vincristine, 
doxorubicin, and dexamethasone.
12
 In the Total Therapy 3 (TT3) trial, with incorporation of 
bortezomib upfront into the tandem transplant regimen, the presence of high-risk features was not 
associated with a shorter event-free survival (EFS) and OS.
26
 A recent published randomized trial 
showed that three cycles of VTD (bortezomib-thalidome-dexamethasone) followed by double 
ASCT induced higher rates of CR or near CR and longer PFS in comparison to TD (thalidomide-
dexamethasone) across subgroups of patients with poor prognostic factors, such as t(4;14) and high 
β2-microglobulin.
20
 
The patient in this case was treated with one of the best available novel three-drug combinations, 
and obtained a very good partial response after five cycles of treatment. The young age and the 
high-risk features of this patient justify an aggressive approach targeting CR. This patient is a 
candidate for a double high-dose chemotherapy with melphalan 200 mg/m
2
 and ASCT approach. 
It is becoming clear that in multiple myeloma, as in other hematologic malignancies, a deeper 
response correlates with longer survival.
27, 28, 29 and 30
 Among patients with high-risk multiple 
myeloma, those who achieve a CR have a longer OS than those who do not. This was demonstrated 
in a landmark survival analysis of 44 patients with high-risk myeloma defined by gene expression 
profiling.
26
 This study demonstrated significantly higher rates of 24-month OS for those achieving a 
CR compared with those who failed to achieve a CR (approximately 80% v 30%, respectively). 
The available data confirm the role of ASCT as standard care for young multiple myeloma patients. 
In patients with high-risk myeloma, the value of ASCT may be augmented by using post-ASCT 
maintenance or consolidation therapy to delay time to relapse. Iterative long-term re-inductions 
with bortezomib-lenalidomide-dexamethasone combinations appear to be promising for patients 
with t(4;14).
31
 In a randomized multicenter trial, the quality of response rates improves across 
induction, transplant, and consolidation, with 60% of patients achieving CR or near CR after 
consolidation post-ASCT.
20
 Importantly, the three-drug approach after consolidation significantly 
improved the probability of molecular remission, thus confirming the results of a previous trial.
29
 
This patient experienced significant toxicity during induction with the three-drug combination. We 
may consider a short consolidation course (four cycles) with lenalidomide plus steroids, followed 
by maintenance with lenalidomide. We have previously shown that a sequential approach including 
bortezomib as induction and ASCT followed by lenalidomide consolidation-maintenance improved 
the quality of response, with 66% of patients achieving CR after lenalidomide/prednisone-
lenalidomide consolidation-maintenance.
32
 The role of lenalidomide maintenance also has been 
investigated in two large trials, the IFM 2005-02 study and the Cancer and Leukemia Group B 
(CALGB) trial, where maintenance with lenalidomide significantly improved PFS, irrespectively of 
risk and quality of response.
33 and 34
 However, the safety of long-term maintenance has been 
questioned because of the issue of second malignancies, and longer follow-up is needed to assess 
benefit in terms of OS. 
In case of an available HLA-matched sibling donor, we would consider the option of an allogeneic 
transplant approach at first relapse. The introduction of reduced-intensity conditioning regimens has 
resulted in excellent responses with lower transplantation-related mortality
35 and 36
 and stimulated 
interest in allogeneic transplantation. However, a recent phase III trial showed that non-
myeloablative allogeneic stem cell transplant after ASCT was not more effective than tandem 
ASCT for patients with standard-risk multiple myeloma.
19
 However, there are data suggesting a role 
of allogeneic transplantation in high-risk patients, where this approach showed that t(4;14) was not 
associated with a worse CR rate or shorter EFS or OS,
37
 but further follow-up is needed before final 
conclusions regarding the utility of ASCT followed by allogeneic stem cell transplant in high-risk 
patients can be made. We think that allogeneic stem cell transplant is reasonable in the setting of a 
clinical trial addressing specifically the issue of high-risk patients. 
In conclusion, fit patients with adverse prognostic factors such as ISS 3 and poor-risk cytogenetic 
abnormalities should probably benefit from a sequential approach and prolonged therapeutic 
schemas, within prospective trials. 
Federica Cavallo, MD, PhD 
Antonio Palumbo, MD 
Department of Hematology 
University of Torino 
Torino, Italy 
EXPERT OPINION 3 
The patient has had an excellent response to the bortezomib, lenalidomide, and dexamethasone 
combination with M protein decreasing from 9.16 g/dL to 0.16 g/dL, albeit at the cost of some side 
effects. Based on her age and lack of other comorbidities, she appears to be a candidate for ASCT. 
We recommend as the next step proceeding with cyclophosphamide and granulocyte colony-
stimulating factor–based stem cell mobilization followed by melphalan-based stem cell transplant, 
which would be considered standard of care at this time. We recommend doing a tandem ASCT in 
her case with the second ASCT being done within 6 months of the first.
38
 This should be followed 
by maintenance with velcade, lenalidomide, and dexamethasone; the duration and dosing will 
depend on tolerance. This recommendation is based on data from TT3, which had 3 years of VRD 
maintenance with 5-year OS approaching 80%. In CALGB 100104 there was a benefit in risk of 
progression and death in the lenalidomide arm compared to placebo after ASCT.
33
 Considering the 
patient’s disease is positive for t(4;14), which is known to be sensitive to bortezomib, it makes 
sense to add this as well. This point is also supported by the Dutch–Belgian Hemato-Oncology 
(HOVON) Cooperative Group study
39
. The addition of lenalidomide for maintenance carries an 
added small risk of secondary malignancies, but at this time the benefit of improvement in survival 
seems to outweigh this risk. 
With advances in therapeutics, EFS and OS outcomes in non-transplant regimens at short follow-up 
times of 2–3 years are comparable to transplant regimens with rates of 80%–90%, but how this pans 
out on long-term follow-up will determine in the next few years if upfront autologous SCT should 
be done or if it is safe to delay this until disease progression or relapse. Until such data are 
available, autologous stem cell transplant should be considered standard of care. 
There is some controversy about the appropriate outcome endpoint for clinical trials in myeloma. It 
is becoming clear that response rates (RR) and CR rates do not correlate well with long-term 
survival in newly diagnosed patients with myeloma and should not be used as primary endpoints. 
As has been pointed out, PFS or more appropriately called “progression-free interval” and OS 
might be better used
40
. There are subgroups of patients who take a long time to achieve CR, while 
having excellent CR duration and OS (eg, molecular subgroup CD-2), while others who are quick to 
achieve CR (eg, molecular subgroup CD-1) have a poorer CR duration and OS.
31 and 41
 CD-1 and 
CD-2 are molecular subgroups of myeloma defined by gene expression profiling.
41
 
If her response to VRD was not adequate the other considerations should again be a bortezomib-
based regimen such as bortezomib/liposomal doxorubicin/ dexamethasone, 
bortezomib/cyclophosphamide/dexamethasone, or VTDPACE 
(bortezomib/thalidomide/dexamethasone/cisplatin/doxorubicin/ cyclophosphamide/etoposide). If 
neuropathy is an issue consideration should be given to administering bortezomib subcutaneously, 
which has a lesser risk of neuropathy. One should avoid alkylators such as melphalan and 
bendamustine prior to stem cell mobilization because of their ability to adversely affect stem cell 
reserve. 
In case the patient is not a candidate for stem cell transplantation because of comorbidities or poor 
functional status, we recommend continuing VRD at lower doses so that she tolerates the treatment 
regimen better and continuing the same regimen even after the patient has achieved CR. If the 
tolerance is poor, two drug regimens might be considered: thalidomide/dexamethasone in case of 
cytopenias and lenalidomide/dexamethasone if neuropathy is a concern. Bortezomib/ 
melphalan/dexamethasone, melphalan/prednisone/thalidomide, melphalan/prednisone, and 
bendamustine/dexamethasone are other options. 
Considering her age, we would not recommend an upfront allogenic stem cell transplant. If there is 
disease relapse within a short interval of ASCT (within 2 years) and if she is in good performance 
status at the time, this should be considered. If not, newer agents such as carfilzomib, 
pomalidomide, elotuzumab, etc, should be considered. 
Bijay Nair, MD, MPHLittle Rock Hematology/Oncology Little Rock, AR 
Sarah Waheed, MD 
Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 
Little Rock, AR 
EXPERT OPINION 4 
The often unassuming veneer over high-risk disease in myeloma makes it appear less dangerous at 
diagnosis. The response proportion is often identical for patients with low- and high-risk disease, 
but patients with high-risk disease quickly reveal themselves when data for PFS and OS become 
apparent. These patients are poorly managed with lenalidomide- or ASCT-based therapies, and 
bortezomib has proven to be the most effective component.
42 and 43
 There are insufficient 
randomized trial data regarding the benefit of tandem transplantation in this group, although results 
from single-arm studies are clearly not encouraging.
44
 
These patients should be referred for novel clinical trials whenever applicable, primarily studying 
novel agents with mechanisms of action previously not explored in myeloma, allogeneic transplants 
with interventions likely to both augment the graft-versus-myeloma effect while easing the burden 
of graft-versus-host disease, or cell therapies targeting unique markers on the myeloma cell surface 
similar to the published advances in chronic lymphocytic leukemia using chimeric antigen 
receptors.
45
 The exact wrong approach is to add on currently available therapies, hoping that this 
Sisyphean task can be achieved with a combination of the drugs we have had available for years. 
With treatments available now, patients with high-risk disease should be treated continuously with 
effort to limit treatment-related mortality—avoiding treatment-induced neutropenic infections, 
disabling bortezomib-related neuropathy, and the now rare event of thalidomide-associated cardiac 
morbidity. The goal is to maximize treatment intensity while not spoiling the patient’s quality of 
life with fatigue, neuropathy, or steroid myopathy. For this patient, early use of autologous 
transplant will provide the maximum benefit of high-dose melphalan, a benefit that appears 
marginal in patients with P53-deleted disease. Maintenance therapy incorporating both 
subcutaneous bortezomib and low-dose lenalidomide until the development of toxicity or 
progression extrapolates the survival benefits from CALGB 100104
33
 and follows the lead of 
Spanish
46
 and Italian phase III trials.
47
 
Craig C. Hofmeister, MD 
Division of Hematology 
Ohio State University 
Columbus, OH 
SUMMARY 
There is significant agreement among experts on most, though not all, major points of management 
in this case. Identification and definition of high risk disease is seen as an important first step in 
management. This is achieved by FISH or gene expression profiling and generally includes such 
mutations as 17p, t(4:14), and t(14:16). The molecular profile may be complemented by more 
traditional features such as ISS stage. Endpoints of therapy such as response rate and CR may be 
imperfect measures or may be achieved only after ongoing therapy with novel agents. PFS, OS, and 
CR duration are more appropriate endpoints. 
Conventional therapies for myeloma such as alkylating agents and corticosteroids are not effective 
in high-risk disease. Newer combinations of proteasome inhibitors and IMiDs are important in high-
risk disease. Bortezomib may overcome high-risk features such as t(4:14) in patients who can 
undergo transplantation. Novel three-drug combinations such as 
bortezomib/lenalidomide/dexamethasone or similar combinations are favored for induction therapy. 
All experts would choose such a combination induction therapy and then proceed to melphalan-
based high-dose therapy and autologous stem cell transplant as a current standard of care for this 
patient’s age and risk group. There is some support among discussants for tandem ASCT based on 
IFM results and other data. Alternative induction regimens can be considered after inadequate 
response to bortezomib/lenalidomide/dexamethasone. 
Perhaps the strongest recommendation given by the panel is the need in this high-risk myeloma 
patient for ongoing maintenance therapy after auto-transplantation. Bortezomib can be given 
subcutaneously to reduce neuropathy with low-dose lenalidomide, maintaining quality of life and 
reducing toxicity. Experts agree these drugs should be used not only at induction but continuously 
in ongoing phases of therapy. Allogeneic transplant would be considered at first relapse by some 
experts but in general is considered exploratory; treatment-related mortality and graft-versus-host 
disease complications make this modality less attractive. 
A repeat bone marrow biopsy/aspirate after five cycles of induction therapy showed normal 
hematopoietic maturation with no morphologic evidence of residual involvement by plasma cell 
myeloma. Skeletal survey was negative. She then underwent stem cell mobilization utilizing 
filgrastim and plerixafor and collected 11.2 x 10
6
/kg CD34 cells. The patient received high-dose 
chemotherapy with melphalan 200 mg/m
2
 with autologous hematopoietic progenitor cell 
transplantation. Her nausea, vomiting, and electrolyte abnormalities were controlled. Pancytopenia 
was treated with red blood cell and platelet transfusions. She had mucositis and neutropenic fever. 
Blood cultures were negative. She was started on intravenous antiobiotics and pain medications for 
the mucositis. Subsequent follow-up showed appropriate recovery with good marrow function. 
Fevers and mucositis resolved. Nausea improved with prednisone. She was able to tolerate her pre-
release medications and drink a sufficient amount of fluids. 
After discharge she experienced pronounced fatigue, anorexia, shortness of breath, palpitations, and 
tachycardia. She developed a cardiomyopathy with evidence of congestive heart failure and ejection 
fractions down to 15%. Whether this is due to chemotherapeutic agents, effects of the stem cell 
transplant, or intercurrent viral infection could not be determined. Subsequently with medical 
therapy, she improved, with echocardiogram ejection fraction increased to 45%. She has no 
evidence of heart failure, although she still has minor shortness of breath when climbing stairs. 
There have been no arrhythmias. Her symptoms improved, and she returned to work full time. She 
lost 70 pounds over 5 months. Other expected toxicities also resolved. 
She started lenalidomide maintenance therapy (10 mg/d) at 4.5 months after the transplant. The 
dose of lenalidomide was reduced to 5 mg daily at 10.5 months after transplant due to leucopenia. 
She remains in CR at 25 months after transplant and is on lenalidomide maintenance. She had no 
other significant adverse effects on lenalidomide. 
Two recent trials of lenalidomide maintenance after stem cell transplantation show improved 
PFS.
33 and 34
 Review of cytogenetic abnormalities is ongoing in one
33
; in the other, adverse 
cytogenetic profiles, including the t(4;14) and the 17p deletion, were more common in the 
lenalidomide group, and patients with a 13q deletion had higher PFS 3 years after randomization in 
patients who received lenalidomide maintenance therapy, as compared with those who received 
placebo.
34
 In another recent double-blind, phase III, multicenter, randomized trial in patients who 
were ineligible for stem cell transplantation, lenalidomide given as part of induction therapy as well 
as in maintenance therapy significantly improved PFS.
48
 An OS benefit may emerge in 
lenalidomide maintenance studies with longer follow-up.
49
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